Sandbox:Mitra: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | | | | | | | | | | | A01 | | | | | | | | | | |A01= <div style="float: Center; text-align: Center; width: 20em; padding:1em;"> '''Therapuetic Considerations in [[Right Ventriculay Myocardial Infarction]] ([[RVMI]]'''| | | |}} | {{familytree | | | | | | | | | | | | | A01 | | | | | | | | | | |A01= <div style="float: Center; text-align: Center; width: 20em; padding:1em;"> '''Therapuetic Considerations in [[Right Ventriculay Myocardial Infarction]] ([[RVMI]])'''| | | |}} | ||
{{familytree | | | | | | | | | | || | |!| | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | | || | |!| | | | | | | | | | | | | | |}} | ||
{{familytree | | | |,|-|-|-|-|v|-|-|-|-|+|-|-|-|v|-|-|-|v|-|-|-|-|.| |}} | {{familytree | | | |,|-|-|-|-|v|-|-|-|-|+|-|-|-|v|-|-|-|v|-|-|-|-|.| |}} | ||
Line 56: | Line 56: | ||
==Don'ts== | ==Don'ts== | ||
* In patients with [[RVMI]], avoid preload-reducing agents such as [[nitrates]], [[diuretics]], [[morphine]], [[beta-blockers]], and [[calcium channel blockers]]. | * In patients with [[RVMI]], avoid preload-reducing agents such as [[nitrates]], [[diuretics]], [[morphine]], [[beta-blockers]], and [[calcium channel blockers]]. | ||
Previously: | |||
{{Family tree/start}} | |||
{{familytree | A01 | A01= <div style="float: left; text-align: left; width: 35em; padding:1em;"> '''Consider right ventricular MI in case of:''' | |||
❑ [[Hypotension]]<br> | |||
❑ Elevated [[jugular venous pressure]]<br> | |||
❑ Clear lung fields<br> | |||
❑ [[ECG]] changes suggestive of an [[inferior MI]] <br> | |||
:❑ ST elevation in leads [[Echocardiogram#Limb Leads|II]], [[Echocardiogram#Limb Leads|III]] and [[Echocardiogram#Limb Leads|aVF]] </div>}} | |||
{{familytree | |!| | }} | |||
{{familytree | B01 | B01= <div style="float: left; text-align: left; width: 35em; padding:1em;">'''Order a right sided ECG in all patients with ST elevation in leads [[II]], [[III]] and [[aVF]]''' <br> | |||
❑ Clearly label the [[ECG]] as right sided to minimize confusion in the emergency room and cath lab<br> | |||
❑ ST-segment elevation of >1 mm in lead V4R suggests a right ventricular [[MI]]</div>}} | |||
{{familytree | |!| | }} | |||
{{familytree | C01 | C01=<div style="float: left; text-align: left; width: 35em; padding:1em;"> | |||
❑ Do not delay the decision and initiation of [[PCI]] vs [[fibrinolytic therapy]]<br> | |||
❑ Do not administer: | |||
:❑ [[Beta blockers]] | |||
:❑ [[Nitrates]] | |||
:❑ [[Diuretics]] | |||
❑ Increase the [[right ventricle]] load by volume expansion with [[normal saline]] preferably with invasive monitoring | |||
:❑ If central hemodynamic monitoring is available, administer normal saline (40 ml/min, up to a total of 2 L, intravenously) until there is an increase in the pulmonary capillary wedge pressure to approximately 15 mmHg <ref name="pmid24222834">{{cite journal| author=Inohara T, Kohsaka S, Fukuda K, Menon V| title=The challenges in the management of right ventricular infarction. | journal=Eur Heart J Acute Cardiovasc Care | year= 2013 | volume= 2 | issue= 3 | pages= 226-34 | pmid=24222834 | doi=10.1177/2048872613490122 | pmc=PMC3821821 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24222834 }} </ref> | |||
:❑ If central hemodynamic monitoring in not available, administer normal saline with a close monitoring of the blood pressure </div>}} | |||
{{familytree | |!| | }} | |||
{{familytree | D01 | D01= <div style="float: left; text-align: left; width: 35em; padding:1em;"> '''If hypotension is not corrected with 1-2 L normal saline:''' | |||
❑ Administer inotropic agents | |||
: ❑ [[Norepinephrine|<span style="color: #000000;">Norepinephrine</span>]] | |||
:: ❑ Initial dose: 0.5–1.0 μg/min | |||
:: ❑ Maximum dose: 30–40 μg/min | |||
:: ❑ Titrate to [[SBP|<span style="color: #000000;">SBP</span>]] >90 mm Hg | |||
: ❑ [[Dopamine|<span style="color: #000000;">Dopamine</span>]] | |||
:: ❑ Cardiac dose: 5.0–10 μg/kg/min | |||
:: ❑ Pressor dose: 10–20 μg/kg/min | |||
:: ❑ Maximum dose: 20–50 μg/kg/min | |||
: ❑ [[Dobutamine|<span style="color: #000000;">Dobutamine</span>]] | |||
:: ❑ Usual dose: 2.0–20 μg/kg/min | |||
:: ❑ Maximum dose: 40 μg/kg/min | |||
:: ❑ Avoid ↑ HR by >10% of baseline | |||
: ❑ [[Milrinone|<span style="color: #000000;">Milrinone</span>]] | |||
:: ❑ Loading dose: 50 μg/kg (slowly over 10 minutes) | |||
:: ❑ Maintenance dose: 0.375–0.75 μg/kg/min | |||
❑ Initiate hemodynamic monitoring with a [[pulmonary catheter]] if possible | |||
</div>}} | |||
{{Familytree/end}} |
Revision as of 16:09, 4 August 2020
Therapuetic Considerations in Right Ventriculay Myocardial Infarction (RVMI) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inotropic support | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Avoidance of preload-reducing agents, such as: • In patients with hypotension (without pulmonary congestion): | • In patients with bradyarrhthmias: • In patients with atrioventricular block:
| • May be needed in patients with cardiogenic shock secondary to RVMI:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Do's
- Right ventricular myocardial infarction (RVMI) should be ruled out in all patients presenting with acute inferior wall myocardial infarction, in particular in patients with hypotension.
- In patients presenting with chest pain and clinical findings of hypotension, elevated JVP and clear lung fields, consider the differential diagnoses of RVMI. These include:
- Systemic or pulmonary vasodilators may be considered in selected patients to reduce RV afterload, thereby improving cardiac output.
- In patients with severe tricuspid regurgitation due to RVMI, replacement of tricuspid valve or repair of the valve with annuloplasty rings may be considered.
- In patients with RVMI who have unexplained hypoxemia despite administration of 100% oxygen, right-to-left shunting -through a patent foramen ovale or atrial septal defect-, caused by the disproportionate elevation in right-sided filling pressures compared to the normal or slightly increased left-sided filling pressures should be considered.
- Patients with extensive necrosis due to RVMI may be at higher risk of right ventricular perforation during interventional procedures. Right ventricular catheterization or pacemaker insertion should be performed with great care in these patients.
Don'ts
- In patients with RVMI, avoid preload-reducing agents such as nitrates, diuretics, morphine, beta-blockers, and calcium channel blockers.
Previously:
Consider right ventricular MI in case of:
❑ Hypotension | |||||||
❑ Do not delay the decision and initiation of PCI vs fibrinolytic therapy
❑ Increase the right ventricle load by volume expansion with normal saline preferably with invasive monitoring
| |||||||
If hypotension is not corrected with 1-2 L normal saline:
❑ Administer inotropic agents
❑ Initiate hemodynamic monitoring with a pulmonary catheter if possible | |||||||
- ↑ Inohara T, Kohsaka S, Fukuda K, Menon V (2013). "The challenges in the management of right ventricular infarction". Eur Heart J Acute Cardiovasc Care. 2 (3): 226–34. doi:10.1177/2048872613490122. PMC 3821821. PMID 24222834.